Baudax Bio Stock (NASDAQ:BXRX)


OwnershipChart

Previous Close

$NaN

52W Range

$0.19 - $0.19

50D Avg

-

200D Avg

-

Market Cap

$8.13M

Avg Vol (3M)

$424.85K

Beta

1.58

Div Yield

-

BXRX Company Profile


Baudax Bio, Inc., a pharmaceutical company, develops and commercializes products for hospital and other acute care settings. The company offers ANJESO (meloxicam) injection for the management of moderate to severe pain, alone or in combination with non-NSAID analgesics. Its products under development includes BX1000, an intermediate-acting neuromuscular blocking agent (NMB) that is in phase II clinical trial; BX2000, an ultra- short acting NMBA, which is in phase I clinical trial; BX3000, an NMBA reversal agent; and Dex-IN, a proprietary intranasal formulation of dexmedetomidine. The company was incorporated in 2019 and is based in Malvern, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

9

IPO Date

Nov 14, 2019

Website

BXRX Performance


Latest Earnings Call Transcripts


Q1 22May 07, 22 | 10:10 AM
Q3 21Nov 04, 21 | 2:57 PM
Q2 21Aug 08, 21 | 3:10 AM

Peer Comparison


TickerCompany
BDRXBiodexa Pharmaceuticals Plc
CFRXContraFect Corporation
CNSPCNS Pharmaceuticals, Inc.
ENSCEnsysce Biosciences, Inc.
QNRXQuoin Pharmaceuticals, Ltd.
YSLakeShore Biopharma Co., Ltd
HILSTharimmune, Inc.
DRMADermata Therapeutics, Inc.
VRAXVirax Biolabs Group Limited
ALLRAllarity Therapeutics, Inc.
CYTOAltamira Therapeutics Ltd.
NRBONeuroBo Pharmaceuticals, Inc.
WINTWindtree Therapeutics, Inc.
PALIPalisade Bio, Inc.